CD274 and neoplasm: In Part 1 of the trial, first-line nivolumab plus ipilimumab showed overall survival (OS) benefit versus chemotherapy in patients with metastatic NSCLC with tumor PD-L1 expression ≥ 1% (independent co-primary endpoint) or < 1% (prespecified descriptive analysis) [1].